The United States Patent and Trademark Office (USPTO) has recently granted a patent to Australia-based clinical-stage cell therapy company Chimeric Therapeutics (ASX: CHM) for its CHM 0201 (CORE-NK) technology, which targets blood cancers and solid tumours. The technology is used in the production of Chimeric’s clinical-stage universal NK cell asset CHM 0201, as well as
Read More
In 2020, the Department of Health and Aged Care revealed that approximately 2,000 Australians were diagnosed with brain cancer. New cases of brain cancer are increasing every year and Glioblastoma, the most common, complex, treatment-resistant, and deadliest type of brain cancer, accounts for 45% of all malignant brain tumours. On a global scale, it is
Read More